Organon Launches New Biosimilars in Canada
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 58 minutes ago
0mins
Source: Newsfilter
- Portfolio Expansion: Organon, in collaboration with Shanghai Henlius Biotech, has launched BILDYOS® and TUZEMTY® biosimilars in Canada, expanding its biosimilars portfolio to eight products across five therapeutic areas, significantly enhancing treatment options for patients nationwide.
- Meeting Market Demand: These denosumab products are used to treat osteoporosis and bone events associated with cancer, addressing the urgent needs of 2.3 million Canadian women, which is expected to improve patient quality of life and alleviate the burden on the healthcare system.
- Deepening Strategic Collaboration: The launch of these products marks a significant step in the partnership between Organon and Henlius, as both companies are committed to providing new treatment options and reinforcing long-term access to biosimilars in the market.
- Focus on Women's Health: By introducing new approved denosumab therapies, Organon strengthens its leadership in women's health, aiming to enhance the resilience of the healthcare system through a patient-centered approach, thereby aiding clinicians and patients in navigating osteoporosis treatment options more flexibly.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy OGN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on OGN
Wall Street analysts forecast OGN stock price to fall
5 Analyst Rating
0 Buy
1 Hold
4 Sell
Strong Sell
Current: 13.430
Low
5.00
Averages
8.50
High
12.00
Current: 13.430
Low
5.00
Averages
8.50
High
12.00
About OGN
Organon & Co. is a global healthcare company. The Company is engaged in developing and delivering health solutions through a portfolio of prescription therapies and medical devices within women's health, biosimilars and a franchise of established medicines across a range of therapeutic areas. It has a portfolio of approximately 70 medicines and products across a range of therapeutic areas. It has a portfolio of contraception and fertility brands, including Nexplanon, NuvaRing, and Follistim AQ. Its Biosimilars portfolio spans across immunology and oncology treatments. It also has a portfolio of established brands, including brands in cardiovascular, dermatology and non-opioid pain management. It sells these products through various channels, including drug wholesalers and retailers, hospitals, government agencies and managed health care providers, such as pharmacy benefit managers and other institutions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Organon Completes Global Licensing Agreement for MIUDELLA
- Licensing Agreement: Organon has completed a global licensing agreement with Sebela Pharmaceuticals, granting exclusive rights to MIUDELLA®, a hormone-free copper IUD expected to launch by late 2026, thereby expanding contraceptive options for women.
- Clinical Trial Results: MIUDELLA demonstrated a 99% efficacy and a 98.8% placement success rate in three clinical trials involving 1,904 women, indicating its strong potential in the contraceptive market to meet women's needs for long-acting reversible birth control.
- Strategic Market Impact: As the first hormone-free copper IUD introduced in the U.S. in over 40 years, MIUDELLA's launch, supported by a REMS program to ensure proper training for healthcare providers, enhances Organon's competitive position in the women's health sector by mitigating risks associated with improper insertion.
- Company Vision: Joe Morrissey, CEO of Organon, emphasized that this agreement strengthens the company's capabilities in contraception, aiming to provide more options that meet women's needs, reflecting a strategic commitment to the global women's health market.
See More
Organon Launches New Biosimilars in Canada
- Portfolio Expansion: Organon, in collaboration with Shanghai Henlius Biotech, has launched BILDYOS® and TUZEMTY® biosimilars in Canada, expanding its biosimilars portfolio to eight products across five therapeutic areas, significantly enhancing treatment options for patients nationwide.
- Meeting Market Demand: These denosumab products are used to treat osteoporosis and bone events associated with cancer, addressing the urgent needs of 2.3 million Canadian women, which is expected to improve patient quality of life and alleviate the burden on the healthcare system.
- Deepening Strategic Collaboration: The launch of these products marks a significant step in the partnership between Organon and Henlius, as both companies are committed to providing new treatment options and reinforcing long-term access to biosimilars in the market.
- Focus on Women's Health: By introducing new approved denosumab therapies, Organon strengthens its leadership in women's health, aiming to enhance the resilience of the healthcare system through a patient-centered approach, thereby aiding clinicians and patients in navigating osteoporosis treatment options more flexibly.
See More
Investigation Alerts for Multiple Company Mergers
- Apogee Acquisition: Apogee Therapeutics is set to be acquired by AbbVie for $135.11 per share in cash, valuing the company at approximately $10.9 billion, with investigations focusing on whether the Apogee Board breached fiduciary duties by failing to conduct a fair process.
- Roku Merger Deal: Roku will be acquired by Fox Corporation for $160.00 per share, with an enterprise value of around $22 billion, as investigations examine whether the Roku Board ensured fair value for shareholders in the transaction.
- TruBridge Acquisition Inquiry: TruBridge is to be acquired by Inventurus Knowledge Solutions for $26.25 per share in cash, with investigations looking into whether the TruBridge Board failed to conduct a fair process, potentially harming shareholder interests.
- Organon Merger Investigation: Organon will be acquired by Sun Pharmaceutical for $14.00 per share in an all-cash deal, with an enterprise valuation of $11.75 billion, as investigations assess whether the Organon Board fulfilled its fiduciary duties to ensure fair value for shareholders.
See More
Arletta Pharma Appoints New Chief Medical Officer
- New Chief Medical Officer: Arletta Pharma Solutions has appointed Dr. Steve van Os as Chief Medical Officer, tasked with leading the clinical development of Lybrido™ in the U.S. and Europe, marking a strategic shift in the company's focus on women's health.
- Clinical Study Preparation: Dr. van Os will oversee the upcoming U.S. Phase II Monarch study aimed at evaluating the efficacy of Lybrido™ for female sexual interest/arousal disorder, which is expected to propel the company's further development in the biopharmaceutical sector.
- Extensive Industry Experience: With over 20 years of global clinical development and regulatory experience, Dr. van Os has held senior positions at Astellas and Organon, successfully driving the global registration of multiple drugs, thereby enhancing Arletta's leadership and market competitiveness.
- Strategic Development Opportunity: This appointment not only strengthens Arletta's medical strategy execution capabilities but also provides new momentum for the company in addressing unmet medical needs for women, likely accelerating the market introduction of Lybrido™.
See More
Investors' Rights Investigation and Potential Violations
- Shareholder Rights Investigation: Halper Sadeh LLC is investigating Open Lending Corporation (NASDAQ: LPRO) for its sale to ANV Group Holdings Ltd. at $3.15 per share, which may infringe on shareholder rights, prompting shareholders to understand their rights and options.
- Cash Acquisition Concerns: Nuvalent, Inc. (NASDAQ: NUVL) is being sold to GSK plc for $124.00 per share in cash, and Halper Sadeh LLC encourages shareholders to be aware of potential compromised rights and to proactively seek legal support.
- Merger Transaction Review: Organon & Co. (NYSE: OGN) is selling to Sun Pharmaceutical Industries Limited for $14.00 per share, and Halper Sadeh LLC may seek to negotiate a higher transaction price and additional disclosures to protect shareholder interests.
- Impact of SUNation Merger: SUNation Energy, Inc. (NASDAQ: SUNE) is merging with Suniva, which is expected to give SUNation shareholders approximately 1.8% ownership in the combined company, and Halper Sadeh LLC will represent shareholders in seeking better transaction terms and rights protection.
See More
Organon Receives FDA Approval for TOFIDENCE New Indications
- FDA Approval for New Indications: Organon announced that its TOFIDENCE (tocilizumab-bavi) injection received FDA approval, expanding its indications to treat severe cytokine release syndrome (CRS) in patients aged 2 and older and hospitalized COVID-19 patients, marking a significant advancement in the biosimilars sector.
- Market Potential Expansion: As the first approved tocilizumab biosimilar in the US, TOFIDENCE is expected to enhance patient access by reducing the financial burden of high-cost brand biologics, thereby strengthening Organon's competitive position in the biopharmaceutical market.
- Multiple Indication Coverage: TOFIDENCE is indicated not only for CRS and COVID-19 but also for rheumatoid arthritis and giant cell arteritis, showcasing its broad clinical application potential and further solidifying Organon's product portfolio.
- Safety Considerations: Patients treated with TOFIDENCE face risks of serious infections, including tuberculosis; Organon emphasizes the need for close monitoring of infection symptoms during treatment to ensure patient safety and optimize therapeutic outcomes.
See More
Organon Completes Global Licensing Agreement for MIUDELLA
- Licensing Agreement: Organon has completed a global licensing agreement with Sebela Pharmaceuticals, granting exclusive rights to MIUDELLA®, a hormone-free copper IUD expected to launch by late 2026, thereby expanding contraceptive options for women.
- Clinical Trial Results: MIUDELLA demonstrated a 99% efficacy and a 98.8% placement success rate in three clinical trials involving 1,904 women, indicating its strong potential in the contraceptive market to meet women's needs for long-acting reversible birth control.
- Strategic Market Impact: As the first hormone-free copper IUD introduced in the U.S. in over 40 years, MIUDELLA's launch, supported by a REMS program to ensure proper training for healthcare providers, enhances Organon's competitive position in the women's health sector by mitigating risks associated with improper insertion.
- Company Vision: Joe Morrissey, CEO of Organon, emphasized that this agreement strengthens the company's capabilities in contraception, aiming to provide more options that meet women's needs, reflecting a strategic commitment to the global women's health market.
See More
Organon Launches New Biosimilars in Canada
- Portfolio Expansion: Organon, in collaboration with Shanghai Henlius Biotech, has launched BILDYOS® and TUZEMTY® biosimilars in Canada, expanding its biosimilars portfolio to eight products across five therapeutic areas, significantly enhancing treatment options for patients nationwide.
- Meeting Market Demand: These denosumab products are used to treat osteoporosis and bone events associated with cancer, addressing the urgent needs of 2.3 million Canadian women, which is expected to improve patient quality of life and alleviate the burden on the healthcare system.
- Deepening Strategic Collaboration: The launch of these products marks a significant step in the partnership between Organon and Henlius, as both companies are committed to providing new treatment options and reinforcing long-term access to biosimilars in the market.
- Focus on Women's Health: By introducing new approved denosumab therapies, Organon strengthens its leadership in women's health, aiming to enhance the resilience of the healthcare system through a patient-centered approach, thereby aiding clinicians and patients in navigating osteoporosis treatment options more flexibly.
See More
Investigation Alerts for Multiple Company Mergers
- Apogee Acquisition: Apogee Therapeutics is set to be acquired by AbbVie for $135.11 per share in cash, valuing the company at approximately $10.9 billion, with investigations focusing on whether the Apogee Board breached fiduciary duties by failing to conduct a fair process.
- Roku Merger Deal: Roku will be acquired by Fox Corporation for $160.00 per share, with an enterprise value of around $22 billion, as investigations examine whether the Roku Board ensured fair value for shareholders in the transaction.
- TruBridge Acquisition Inquiry: TruBridge is to be acquired by Inventurus Knowledge Solutions for $26.25 per share in cash, with investigations looking into whether the TruBridge Board failed to conduct a fair process, potentially harming shareholder interests.
- Organon Merger Investigation: Organon will be acquired by Sun Pharmaceutical for $14.00 per share in an all-cash deal, with an enterprise valuation of $11.75 billion, as investigations assess whether the Organon Board fulfilled its fiduciary duties to ensure fair value for shareholders.
See More
Arletta Pharma Appoints New Chief Medical Officer
- New Chief Medical Officer: Arletta Pharma Solutions has appointed Dr. Steve van Os as Chief Medical Officer, tasked with leading the clinical development of Lybrido™ in the U.S. and Europe, marking a strategic shift in the company's focus on women's health.
- Clinical Study Preparation: Dr. van Os will oversee the upcoming U.S. Phase II Monarch study aimed at evaluating the efficacy of Lybrido™ for female sexual interest/arousal disorder, which is expected to propel the company's further development in the biopharmaceutical sector.
- Extensive Industry Experience: With over 20 years of global clinical development and regulatory experience, Dr. van Os has held senior positions at Astellas and Organon, successfully driving the global registration of multiple drugs, thereby enhancing Arletta's leadership and market competitiveness.
- Strategic Development Opportunity: This appointment not only strengthens Arletta's medical strategy execution capabilities but also provides new momentum for the company in addressing unmet medical needs for women, likely accelerating the market introduction of Lybrido™.
See More
Investors' Rights Investigation and Potential Violations
- Shareholder Rights Investigation: Halper Sadeh LLC is investigating Open Lending Corporation (NASDAQ: LPRO) for its sale to ANV Group Holdings Ltd. at $3.15 per share, which may infringe on shareholder rights, prompting shareholders to understand their rights and options.
- Cash Acquisition Concerns: Nuvalent, Inc. (NASDAQ: NUVL) is being sold to GSK plc for $124.00 per share in cash, and Halper Sadeh LLC encourages shareholders to be aware of potential compromised rights and to proactively seek legal support.
- Merger Transaction Review: Organon & Co. (NYSE: OGN) is selling to Sun Pharmaceutical Industries Limited for $14.00 per share, and Halper Sadeh LLC may seek to negotiate a higher transaction price and additional disclosures to protect shareholder interests.
- Impact of SUNation Merger: SUNation Energy, Inc. (NASDAQ: SUNE) is merging with Suniva, which is expected to give SUNation shareholders approximately 1.8% ownership in the combined company, and Halper Sadeh LLC will represent shareholders in seeking better transaction terms and rights protection.
See More
Organon Receives FDA Approval for TOFIDENCE New Indications
- FDA Approval for New Indications: Organon announced that its TOFIDENCE (tocilizumab-bavi) injection received FDA approval, expanding its indications to treat severe cytokine release syndrome (CRS) in patients aged 2 and older and hospitalized COVID-19 patients, marking a significant advancement in the biosimilars sector.
- Market Potential Expansion: As the first approved tocilizumab biosimilar in the US, TOFIDENCE is expected to enhance patient access by reducing the financial burden of high-cost brand biologics, thereby strengthening Organon's competitive position in the biopharmaceutical market.
- Multiple Indication Coverage: TOFIDENCE is indicated not only for CRS and COVID-19 but also for rheumatoid arthritis and giant cell arteritis, showcasing its broad clinical application potential and further solidifying Organon's product portfolio.
- Safety Considerations: Patients treated with TOFIDENCE face risks of serious infections, including tuberculosis; Organon emphasizes the need for close monitoring of infection symptoms during treatment to ensure patient safety and optimize therapeutic outcomes.
See More
